Highlights:
-
Highly synergistic with Agilent’s current customer-base and sales
channel
-
Enables complete LC and LC/MS workflow solutions in important
glycan biopharma segment
-
Strengthens Agilent’s customer value proposition in fast-growing
biopharma market
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jun. 28, 2018--
Agilent Technologies Inc. (NYSE: A) today announced that it has entered
into a definitive agreement to acquire privately-held ProZyme, Inc., a
leading provider of glycan analysis reagents, kits and standards. This
acquisition will expand Agilent’s portfolio of biopharma consumables in
the fast-growing glycan market.
“Agilent is focused on being a complete workflow solutions provider,”
said Mark Doak, president of Agilent’s CrossLab Group. “We have a strong
installed base of customers worldwide, and expanding our consumables
portfolio is key to our strategy of providing a seamless customer
experience and helping our customers reduce the cost and time required
to bring new therapeutics to market.”
Founded in 1990, ProZyme is an industry leading developer and
manufacturer of glycan reagents, kits and standards, which are required
for efficient sample prep in the analysis of free glycans. Glycobiology,
which is the study of the structure, function and biology of
carbohydrates, also called glycans, is a fast-growing and important
field of study in life sciences. Glycans play diverse roles in
biotherapeutics, novel drug development, the study of bacterial
physiology, and proteomics research.
“Glycan analysis is essential to the discovery, development, and quality
control testing of the ever-growing pipeline of biotherapeutic drug
products,” said Padraig McDonnell, vice president and general manager of
Agilent’s Chemistries and Supplies Division. “ProZyme is a market leader
and innovator in the glycan consumable space. This acquisition provides
greater scale to our biopharma consumables business and enhances our
value proposition by enabling complete glycan liquid chromatography and
mass spectrometry workflow solutions.”
“ProZyme and Agilent make a perfect strategic fit,” said Sergey
Vlasenko, president and CEO of ProZyme. “Our glycobiology and
glycoanalysis expertise together with Agilent’s market-leading position
in LC and LC/MS will allow us to provide our biopharma customers with
complete solutions they need to accelerate their research.”
ProZyme is headquartered in Hayward, California, and employs 47 people.
The transaction is subject to closing conditions. Financial terms of the
deal are not being disclosed.
About ProZyme, Inc.
ProZyme Inc. is a privately-owned company dedicated to advancing
glycobiology research and improving biopharmaceutical analysis for
optimal design and quality manufacturing of life saving therapies. The
company supplies value-added kits, enzymes, standards and a complete CE
system for biotherapeutic protein characterization and glycobiology
research. ProZyme’s focus on R&D and innovation supports an agile
product development program and a strong IP portfolio. Information about
ProZyme is available at www.prozyme.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to its customers' most
challenging questions. The company generated revenues of $4.47 billion
in fiscal 2017 and employs 14,200 people worldwide. Information about
Agilent is available at www.agilent.com.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the
Securities Exchange Act of 1934 and is subject to the safe harbors
created therein. The forward-looking statements contained herein
include, but are not limited to, statements regarding the capabilities
and expertise the acquisition brings, the ability to supply industry
requirements and acceleration of growth. These forward-looking
statements involve risks and uncertainties that could cause Agilent’s
results to differ materially from management’s current expectations.
Such risks and uncertainties include, but are not limited to, the
ProZyme transaction not being timely completed, if completed at all, and
the ability to integrate ProZyme’s operations with Agilent’s, retain key
employees, meet customer expectations and realize efficiencies from the
combined businesses. In addition, other risks that Agilent faces in
running its operations include the ability to execute successfully
through business cycles; the ability to meet and achieve the benefits of
its cost-reduction goals and otherwise successfully adapt its cost
structures to continuing changes in business conditions; ongoing
competitive, pricing and gross-margin pressures; the risk that our
cost-cutting initiatives will impair our ability to develop products and
remain competitive and to operate effectively; the impact of
geopolitical uncertainties and global economic conditions on our
operations, our markets and our ability to conduct business; the ability
to improve asset performance to adapt to changes in demand; the ability
of our supply chain to adapt to changes in demand; the ability to
successfully introduce new products at the right time, price and mix;
the ability of Agilent to successfully integrate recent acquisitions;
the ability of Agilent to successfully comply with certain complex
regulations; and other risks detailed in Agilent’s filings with the
Securities and Exchange Commission, including our quarterly report on
Form 10-Q for the quarter ended April 30, 2018. Forward-looking
statements are based on the beliefs and assumptions of Agilent’s
management and on currently available information. Agilent undertakes no
responsibility to publicly update or revise any forward-looking
statement.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available on the Agilent news site at www.agilent.com/go/news.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180628006116/en/
Source: Agilent Technologies Inc.
Agilent Technologies:
EDITORIAL CONTACTS:
Victoria
Wadsworth-Hansen (Business), +1 408-553-2005
+ 45 29336980
victoria.wadsworth-hansen@agilent.com
or
Stefanie
Notaney (Enterprise), +1 408-345-8955
stefanie.notaney@agilent.com
or
INVESTOR
CONTACT:
Ruben Dirado, +1 408-345-8971
ruben_dirado@agilent.com